Medicine Online
Any medical inquiries? Search MOL for answers:
NEWS
Home > News > 2006 > February > 23 > Methotrexate Fights Rheumatoid Arthritis Second Time Around
Medical References
Diseases & Conditions
Women's Health
Mental Health
Men's Health
Healthy Choice News
Site Map Links
Medical Tips
Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that may be programmed into our metabolic systems.
Read more health news

Methotrexate Fights Rheumatoid Arthritis Second Time Around

THURSDAY, Feb. 23 (HealthDay News) -- A second course of the drug methotrexate can still prove effective in rheumatoid arthritis patients who didn't respond to the drug the first time around, Austrian researchers report.

Investigators at the Medical University of Vienna also found that a second treatment was particularly effective in patients who received low doses of the drug in their first treatment.

Methotrexate is the most commonly used drug to treat rheumatoid arthritis.

The study, published in the Feb. 23 issue of Arthritis Research & Therapy, involved 79 patients who had a second methotrexate treatment that lasted at least a year. The patients had stopped their first treatment due to side effects, or because it was ineffective.

Of these 79 patients, 42 (53.2 percent) went on to gain benefit from an effective second treatment. Of those patients, 23 had stopped their first treatment because it was ineffective and 16 had stopped their first treatment due to side effects.

The second treatment was more than twice as likely to be effective in patients who had received a low dose (10 milligrams or less per week) in their first treatment than in patients who received a high dose (more than 17.5 milligrams per week) in their first treatment.

The findings suggest that renewed use of methotrexate may be an option for treatment of rheumatoid arthritis patients who failed to respond to their first treatment with the drug, the researchers said.


HealthDay
HomeSitemap Contact UsAdvertisingPress RoomGive Us Your FeedbackRead Our Terms & Conditions and Our DisclaimerPrivacy Statement